Corrie, P. G.
Qian, W.
Basu, B.
Valle, J. W. http://orcid.org/0000-0002-1999-0863
Falk, S.
lwuji, C.
Wasan, H.
Palmer, D.
Scott-Brown, M.
Wadsley, J.
Arif, S.
Bridgewater, J. http://orcid.org/0000-0001-9186-1604
Propper, D.
Gillmore, R.
Gopinathan, A.
Skells, R.
Bundi, P.
Brais, R.
Dalchau, K.
Bax, L.
Chhabra, A.
Machin, A.
Dayim, A.
McAdam, K.
Cummins, S.
Wall, L.
Ellis, R.
Anthoney, A.
Evans, J.
Ma, Y. T.
Isherwood, C.
Neesse, A.
Tuveson, D.
Jodrell, D. I.
Article History
Received: 29 October 2019
Revised: 19 March 2020
Accepted: 1 April 2020
First Online: 30 April 2020
Ethics approval and consent to participate
: The SIEGE trial protocol (ISRCTN71070888) was approved by the Northern Ireland Research Ethics Committee3 and was performed in accordance with the Declaration of Helsinki and the EU Clinical Trials Directive 2001/20/EC. All patients provided written informed consent.
: Not applicable.
: The SIEGE trial data is held by the Cambridge Clinical Trials Unit—Cancer Theme. Ownership of the data resides with the Trial Management Group (TMG). Access to the data can be requested and authorised by the TMG.
: The following conflicts of interest are declared, which were incurred during the conduct of the SIEGE: Dr Corrie was the lead recipient of the SIEGE research grant from Celgene, which was paid to Cambridge University NHS Foundation Trust. Dr Basu and Dr Propper received funding from Celgene for research work outside of the SIEGE trial. Professor Bridgewater, Dr Corrie, Professor Evans, Professor Palmer, Professor Wadsley and Dr Wassan report personal fees from Celgene for advisory boards and/or speaker fees. Dr Falk, Professor Valle and Dr Basu received a travel grant from Celgene. Dr Propper was an expert witness when nab-Paclitaxel was submitted for NICE evaluation in 2017. Professor Evans is an editor of the clinical subject section of the <i>British Journal of Cancer.</i> Dr Falk and Dr Basu are Editorial Board members of the <i>British Journal of Cancer</i>. The remaining authors declare no competing interests.
: Grant funding was provided by Celgene Sarl [Celgene reference number AX-PANC-PI-0101]. The funder had no role in study design, data collection, analysis, interpretation or writing of the report.